Lubiprostone
- Atc Codes:A06AX03
- CAS Codes:136790-76-6
- PHARMGKB ID:136790-76-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Amitiza.
Drug combinations
Chemistry
Lubiprostone: C~20~H~32~F~2~O~5~. Mw: 390.46. (1) Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11α)-; (2)(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid. CAS-136790-76-6 (2002).
Pharmacologic Category
GI Drugs, Miscellaneous; Chloride Channel Activator. (ATC-Code: A06AX03).
Mechanism of action
Bicyclic fatty acid that acts locally at apical portion of intestine as a chloride channel activator, increasing intestinal fluid secretion and intestinal motility. Does not alter serum sodium or potassium concentrations.
Therapeutic use
Treatment of chronic idiopathic constipation. Treatment of irritable bowel syndrome with constipation in adult women.
Pregnancy and lactiation implications
Animal studies suggest lubiprostone may cause fetal loss; teratogenic effects not observed. There are no adequate, well-controlled studies in pregnant women. Use not recommended during lactation.
Unlabeled use
Contraindications
Known or suspected mechanical bowel obstruction.
Warnings and precautions
Dyspnea observed. Nausea might occur. Avoid use in severe diarrhea. Use contraindicated in bowel obstruction. Use with caution in hepatic and renal impairment. Not approved for use in males with irritable bowel syndrome with constipation.